ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för saxagliptin hydrate. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

13 träffar

Bibliografisk träff 2012-08-01

Overcoming bioanalytical challenges in an Onglyza(®) intravenous [(14)C]microdose absolute bioavailability study with accelerator MS.

Xu XS, Dueker SR, Christopher LJ, Lohstroh PN, Keung CF, Cao KK, Bonacorsi SJ, Cojocaru L, Shen JX, Humphreys WG, Stouffer B, Arnold ME.

Bioanalysis · validation study; journal article · DOI 10.4155/bio.12.171

Bibliografisk träff 2012-07-09

Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen(®), a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women.

Upreti VV, Hsiang CB, Li L, Xu X, LaCreta FP, Boulton DW.

Diabetes Obes Metab · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/j.1463-1326.2012.01635.x

Bibliografisk träff 2012-02-06

Liquid chromatography and tandem mass spectrometry method for the quantitative determination of saxagliptin and its major pharmacologically active 5-monohydroxy metabolite in human plasma: method validation and overcoming specific and non-specific binding at low concentrations.

Xu XS, Demers R, Gu H, Christopher LJ, Su H, Cojocaru L, Boulton DW, Kirby M, Stouffer B, Humphreys WG, Arnold ME.

J Chromatogr B Analyt Technol Biomed Life Sci · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jchromb.2012.01.033

Bibliografisk träff 2012-01-01

Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.

Yang LP.

Drugs · review; journal article · DOI 10.2165/11208160-000000000-00000

Bibliografisk träff 2011-11-17

Kinetic and mechanistic insight into the thermodynamic degradation of saxagliptin.

Jones GS, Savage SA, Ivy S, Benitez PL, Ramirez A.

J Org Chem · journal article · DOI 10.1021/jo202052a

Bibliografisk träff 2011-10-15

Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden.

Granström O, Bergenheim K, McEwan P, Sennfält K, Henriksson M.

Prim Care Diabetes · comparative study; randomized controlled trial; journal article · DOI 10.1016/j.pcd.2011.09.003

Bibliografisk träff 2011-04-01

Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.

Boulton DW, Li L, Frevert EU, Tang A, Castaneda L, Vachharajani NN, Kornhauser DM, Patel CG.

Clin Pharmacokinet · controlled clinical trial; research support, non-u.s. gov't; journal article · DOI 10.2165/11584350-000000000-00000

Bibliografisk träff 2010-10-21

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

Kulasa K, Edelman S.

Core Evid · review-article; journal article · DOI 10.2147/ce.s8006

Bibliografisk träff 2010-09-22

Saxagliptin for type 2 diabetes.

Chacra AR.

Diabetes Metab Syndr Obes · review-article; journal article · DOI 10.2147/dmsott.s12241

Bibliografisk träff 2010-09-01

[Saxagliptin (Onglyza): new inhibitor of the dipeptidylpeptidase-4 for the oral treatment of type 2 diabetes].

Scheen AJ.

Rev Med Liege · journal article; english abstract

Bibliografisk träff 2010-07-01

Saxagliptin: a new drug for the treatment of type 2 diabetes.

Thareja S, Aggarwal S, Malla P, Haksar D, Bhardwaj TR, Kumar M.

Mini Rev Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.2174/138955710791572424

Bibliografisk träff 2010-05-11

Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes.

Borja-Hart NL, Whalen KL.

Ann Pharmacother · review; journal article · DOI 10.1345/aph.1p003

Bibliografisk träff 2009-11-01

Saxagliptin (Onglyza) for type 2 diabetes.

Författaruppgift saknas

Med Lett Drugs Ther · journal article · DOI 10.1097/01.aog.0000371637.82093.54